Fundamentals for Edwards Lifesciences Corporation
The analysts' recent buy bias for EW indicates strong confidence in the stock's future performance. This could encourage more investors to view EW as a worthwhile investmen...
Business Operations:
Sector: HealthcareIndustry: Medical Devices
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Revenue projections:
Financial Ratios:
| currentRatio | 4.597000 |
|---|---|
| forwardPE | 31.242527 |
| debtToEquity | 6.427000 |
| earningsGrowth | 0.067000 |
| revenueGrowth | 0.105000 |
| grossMargins | 0.780180 |
| operatingMargins | 0.288180 |
| trailingEps | 1.720000 |
| forwardEps | 3.386410 |
EW's current ratio of 4.597 shows that the company has ample resources to service its short-term debt. This indicates a solid financial position, as EW can rely on its cash reserves and current assets to cover its immediate liabilities without strain.
EW's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
Edwards Lifesciences Corporation's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that Edwards Lifesciences Corporation is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.
Price projections:
Insider Transactions:
37 sell transactions of EW were recorded, with market price hovering near 85.8345947265625.There were no sell transactions during the period under consideration.The trend of more buys than sells at EW's current price levels suggests a possible bullish sentiment. This could indicate that investors are expecting a favorable outlook for the stock, prompting more buying activity.
Recommendation changes over time:
The analysts' recent buy bias for EW indicates strong confidence in the stock's future performance. This could encourage more investors to view EW as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.